MiRNA-199a-3p in Plasma as a Potential Diagnostic Biomarker for Gastric Cancer

BackgroundMicroRNA (miRNA) has been shown the potential of cancer diagnosis. We investigated whether plasma miRNA expression could discriminate between patients with and without gastric cancer.MethodsThis study was divided into three steps: (1) miRNA microarray profiling on plasma samples from 20 gastric cancer patients and 20 healthy controls; (2) miRNA selection by real-time qRT-PCR on 30 pairs of plasma from patients and controls; and (3) qRT-PCR validation on an independent set of plasma from 180 gastric cancer patients, 80 healthy controls, and 20 patients with gastric precancerous diseases.ResultsOf the 959 human miRNAs analyzed by microarray, 37 up-regulated miRNAs and seven down-regulated miRNAs were found in gastric cancer plasma. Of the seven discrepant miRNAs validated on the plasma from 30 gastric cancer patients and 30 healthy controls, both miRNA-199a-3p and miRNA-151-5p were significantly elevated (p < 0.05) and were significantly reduced after surgery (p < 0.05) in gastric cancer patients. Further large-scale validation showed that these two miRNAs expressions in plasma were significantly higher in gastric cancer patients than healthy controls and patients with gastric precancerous diseases, respectively. However, only the expression of miRNA-199a-3p in plasma was significantly associated with tumor invasion and with lymph node metastasis and tumor, node, metastasis stage. This marker yielded an area under the receiver operating characteristic curve area of 0.837 with 80 % sensitivity and 74 % specificity in discriminating gastric cancer patients from healthy controls. In gastric cancer tissue, miRNA-199a-3p was expressed in the cytoplasm of tumor cells.ConclusionsmiRNA-199a-3p in plasma could be a novel potential diagnostic biomarker for gastric cancer detection.

[1]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[2]  Jian Li,et al.  miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. , 2010, Biological & pharmaceutical bulletin.

[3]  Tao Yu,et al.  The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster , 2009, Journal of experimental & clinical cancer research : CR.

[4]  L. Martins,et al.  CA72-4 antigen levels in serum and peritoneal washing in gastric cancer. Correlation with morphological aspects of neoplasia. , 2007, Arquivos de gastroenterologia.

[5]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[6]  Chien-Jen Chen,et al.  Evaluation of Risk Factors for Nasopharyngeal Carcinoma in High-Risk Nasopharyngeal Carcinoma Families in Taiwan , 2005, Cancer Epidemiology Biomarkers & Prevention.

[7]  C. Haglund,et al.  CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. , 2002, Anticancer research.

[8]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[9]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[10]  H. Bonnefoi,et al.  Telomerase RNA as a detection marker in the serum of breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Xiaohua Li,et al.  Survival prediction of gastric cancer by a seven-microRNA signature , 2009, Gut.

[12]  C. Croce,et al.  MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. , 2010, Cancer research.

[13]  D. Ichikawa,et al.  Circulating microRNAs in plasma of patients with gastric cancers , 2010, British Journal of Cancer.

[14]  Hansjuerg Alder,et al.  The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. , 2009, Gynecologic oncology.

[15]  S. Leung,et al.  Analysis of cell-free Epstein-Barr virus associated RNA in the plasma of patients with nasopharyngeal carcinoma. , 1999, Clinical chemistry.

[16]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[17]  R. Soetikno,et al.  Endoscopic submucosal dissection of early gastric cancer , 2006, Journal of Gastroenterology.

[18]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[19]  George A Calin,et al.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. , 2008, Blood.

[20]  Xi Chen,et al.  A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.

[21]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[22]  Li Lin,et al.  Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. , 2011, Cancer cell.

[23]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[24]  T. Leung,et al.  Detection and characterization of placental microRNAs in maternal plasma. , 2008, Clinical chemistry.

[25]  Jacques Ferlay,et al.  Estimates of cancer incidence in China for 2000 and projections for 2005. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  Y. Lo,et al.  Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  G. Gerken,et al.  Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion , 2010, Molecular Cancer.